Live IPO - AF Legal Group

AF legal.png

ANS has successfully commercialised a number of products in the Hong Kong market with distributions Australian Family Lawyers (AFL), is an Australian law firm that practices family and relationship law. The firm provides advice to clients in respect of divorce, separation, property and children’s matters together with ancillary services such as litigation, wills and estates.

AFL is a law firm with a difference. It was established in 2015 by Edward Finn (Founder and Managing Director) who identified an opportunity to create a disruptive law firm that challenged the conventional wisdom of relationship driven business development and instead applied an alternative model driven by data and digital marketing. The Company’s business model combines cost effective revenue generation and operating efficiencies to achieve higher profitability metrics than benchmarked traditional competitors.

With revenues of $4.8 million in FY2018, an increase of 86.9% on FY2017, the Company has shown significant growth along with an EBITDA margin of over 27% for H1 FY2019.

The Family Law market in Australia is worth an estimated $1.1 billion in revenue and is highly fragmented and well suited for consolidation. No family law firm currently has an identified national presence. AFL’s objective is to become the market leading provider of Family Law services in Australia..

  • Pay by: April 29

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: $10,000 (before scaling).

  • Prospectus

Closed.

Live IPO - Australian Nutrition and Sports Ltd.

ANS.png

Australian Nutrition & Sports Ltd (ASX: AN1) is an Australian based company, committed to developing, sourcing and marketing high quality Australian made milk formula and nutrition and wellness products for sale in China, Hong Kong and Australia. In the future they plan to expand into other Asian markets.

Currently focused on infant and adult milk formula products, protein based health and wellness nutritional products, ANS’s business model is to develop and brand its own high-quality products, and then to develop distribution channels for the profitable sale of the products. In doing this ANS currently intends to rely on a capital light business model by outsourcing the production of its products to various export accredited Australian third-party producers.

ANS has successfully commercialised a number of products in the Hong Kong market with distributions agreements in places with leading pharmacy groups including Watsons and Mannings. In FY2018, ANS generated cash sales of $419,260, up 192% from FY2017 sales of $218,033.

  • Pay by: March 25

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: No Limit.

  • Prospectus

Closed.

Live IPO - Expose Resources Ltd.

expose resources.png

Expose Resources (proposed ASX: EXX) is focused on exploring and developing high quality gold projects in Australia.

The flagship project is the Red Gate Gold Project located 10km north of Saracen Minerals’ (ASX: SAR) Porphyry Gold Mine in the prolific Eastern Goldfields of WA.

The Company has a fully approved 3,000m RC drill program planned to commence immediately on listing, designed to follow up and extend previous multiple intersections of broad, near-surface high-grade gold mineralization. The Project also hosts multiple other high priority targets which will be systematically drilled.

Recently EXX also effectively expanded Red Gate via an earn-in JV with GFI to earn up to 85% of the tenement adjacent to the East, importantly capturing an additional 3km strike length of the Reidys prospect.

The Company’s second project is the Roger River Gold Project in north-west Tasmania which represents an early stage epithermal-style project with large-scale discovery potential. A maiden drilling program at this target is also planned on listing.

The Company has assembled an experienced management, exploration and development team who are well qualified to exploit the potential of the Company’s mineral assets.

  • Pay by: March 22

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: No Limit.

  • Prospectus

Closed

Live IPO - Australian Industrial Minerals Ltd.

aim.png

Australian Industrial Minerals Ltd (ASX: AAM) ) has acquired 100% of Australian Abrasive Minerals Pty Ltd which holds the Harts Range Project, located 140km northeast of Alice Springs in the Northern Territory. The Project has JORC 2012 compliant Ore Reserves that support an initial mine life of 9.25 years, with Measured and Inferred Mineral Resources with potential to extend the mine life.  The Ore Reserves and Mineral Resources contain the complete range of garnet grain particle sizes required for industrial abrasive applications.

AAM’s objective is to extract, process and sell industrial abrasives (principally garnet) from an easily accessible alluvial sand deposit. These abrasives are used in abrasive blast cleaning, waterjet cutting and water filtration applications. The Company’s primary objective is to maximise production at the Project and leverage off the continued global demand for a reliable supplier of environmentally friendly abrasive products. The Company is also pursuing a strategy to become a diverse industrial minerals producer and supplier, by acquiring production-ready industrial mineral opportunities that are a strategic fit for the Company.

  • Pay by: March 8

  • List Price: $0.25

  • Minimum Investment: $2,000

  • Maximum Investment: $10,000

  • Prospectus

Closed

Live IPO - Koligo Therapeutics Ltd.

1527368198KoligoTherapeutics_logo.jpg

Koligo Therapeutics Ltd (ASX: KOL) was incorporated on 27 June 2018 for the primary purpose of acquiring Koligo Therapeutics, Inc (Koligo) a US biotechnology company focused on the development and commercialisation of a range of cell therapy, three-dimensional (3D) bioprinted tissue and other regenerative medicine products for serious unmet medical needs.

Koligo has successfully commercialised and has recently commenced selling its first cell therapy transplant product, Kyslecel™, for the treatment of chronic pancreatitis patients, in the United States.  Kyslecel™ is used in the treatment of patients suffering from chronic or acute recurrent pancreatitis, a debilitating and painful condition with few effective treatment options. Since 14 months ago, when sales commenced to a limited number of initial hospital customers, Koligo has generated revenues of approximately $1,600,000 from sales of this product.  

Koligo is currently developing Kyslecel™ v2.0, an improved formulation that is intended to extend the product’s shelf life and thus expand Koligo’s geographic reach. Koligo also seeks to develop and commercialize a range of other transformative cell therapies for a range of indications, including type 1 diabetes, and other pancreatic diseases; as well as 3D printed pre-vascularised cell/tissue structures for multiple indications, including liver failure, neurological diseases, metabolic disorders, and genetic disorders. Oversimplifying somewhat, pre-vascularised cell/tissue structures are 3D bio-printed for transplantation into humans with blood vessels already embedded in the tissue.

  • Pay by: April 5

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: $10,000

  • Prospectus

Closed